Study: NCT01184092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).